ORIC Pharmaceuticals, Inc.
ORIC
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$14.20
Price+2.31%
$0.32
1Y
Price
Market Cap
$1.470b
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$135.214m
-4.4%
1y CAGR-10.9%
3y CAGR-11.4%
5y CAGREPS
-$1.44
+2.0%
1y CAGR+9.5%
3y CAGR+10.3%
5y CAGRBook Value
$415.557m
$436.762m
Assets$21.205m
Liabilities$3.296m
DebtDebt to Assets
0.8%
-
Debt to EBITDAFree Cash Flow
-$111.362m
+2.4%
1y CAGR-9.8%
3y CAGR-10.4%
5y CAGRNo items found.
Press Releases
Statements and updates from the company